Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Inflammatory Bowel Diseases | 17 | 2022 | 562 | 3.200 |
Why?
|
Capsule Endoscopy | 4 | 2023 | 33 | 2.570 |
Why?
|
Colitis, Ulcerative | 13 | 2024 | 722 | 2.410 |
Why?
|
Short Bowel Syndrome | 3 | 2024 | 38 | 2.350 |
Why?
|
Gastrointestinal Agents | 5 | 2024 | 166 | 1.810 |
Why?
|
Liver Diseases | 5 | 2024 | 242 | 1.780 |
Why?
|
Gastrointestinal Hemorrhage | 8 | 2023 | 235 | 1.490 |
Why?
|
Parenteral Nutrition | 5 | 2024 | 61 | 1.480 |
Why?
|
Liver | 4 | 2024 | 1235 | 1.400 |
Why?
|
Nutrition Therapy | 2 | 2020 | 11 | 1.370 |
Why?
|
Intestinal Diseases | 3 | 2020 | 79 | 1.360 |
Why?
|
Crohn Disease | 9 | 2022 | 744 | 1.250 |
Why?
|
Clostridium Infections | 6 | 2022 | 125 | 1.170 |
Why?
|
Autoimmune Diseases | 8 | 2021 | 244 | 1.120 |
Why?
|
Humans | 89 | 2024 | 87555 | 1.070 |
Why?
|
Biosimilar Pharmaceuticals | 4 | 2020 | 22 | 1.050 |
Why?
|
Neoplasms | 7 | 2024 | 2970 | 1.050 |
Why?
|
Nutrition Assessment | 2 | 2021 | 21 | 0.940 |
Why?
|
Rheumatic Diseases | 2 | 2021 | 20 | 0.940 |
Why?
|
Hospitalization | 8 | 2023 | 858 | 0.930 |
Why?
|
Gastroenterology | 2 | 2018 | 143 | 0.930 |
Why?
|
Infliximab | 4 | 2020 | 152 | 0.900 |
Why?
|
Retrospective Studies | 20 | 2024 | 8713 | 0.890 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2023 | 19 | 0.880 |
Why?
|
Vaccination | 2 | 2022 | 264 | 0.880 |
Why?
|
Peptides | 2 | 2024 | 644 | 0.880 |
Why?
|
Colitis | 3 | 2021 | 241 | 0.870 |
Why?
|
Enterocolitis | 1 | 2022 | 12 | 0.850 |
Why?
|
Opportunistic Infections | 1 | 2022 | 59 | 0.830 |
Why?
|
Peritoneal Neoplasms | 2 | 2023 | 181 | 0.820 |
Why?
|
Patient Readmission | 4 | 2024 | 340 | 0.820 |
Why?
|
Intestine, Small | 3 | 2023 | 303 | 0.810 |
Why?
|
Cathartics | 1 | 2021 | 27 | 0.810 |
Why?
|
Immune System Diseases | 2 | 2019 | 26 | 0.790 |
Why?
|
Cytomegalovirus Infections | 1 | 2022 | 145 | 0.790 |
Why?
|
Endoscopy, Gastrointestinal | 2 | 2021 | 154 | 0.790 |
Why?
|
Enterocolitis, Pseudomembranous | 7 | 2015 | 52 | 0.780 |
Why?
|
Vaccines | 1 | 2022 | 81 | 0.780 |
Why?
|
Malnutrition | 1 | 2021 | 34 | 0.750 |
Why?
|
Nasturtium | 1 | 2020 | 4 | 0.740 |
Why?
|
Fasciola hepatica | 1 | 2020 | 5 | 0.740 |
Why?
|
Antibodies, Helminth | 1 | 2020 | 11 | 0.740 |
Why?
|
Fascioliasis | 1 | 2020 | 6 | 0.740 |
Why?
|
Dyspepsia | 1 | 2020 | 10 | 0.740 |
Why?
|
Neuroendocrine Tumors | 2 | 2019 | 108 | 0.720 |
Why?
|
Angiodysplasia | 1 | 2019 | 4 | 0.710 |
Why?
|
Spiders | 1 | 2019 | 14 | 0.700 |
Why?
|
Eosinophilia | 1 | 2020 | 85 | 0.700 |
Why?
|
Bone Resorption | 1 | 2019 | 42 | 0.690 |
Why?
|
Biological Products | 1 | 2021 | 146 | 0.690 |
Why?
|
Risk Factors | 17 | 2024 | 5373 | 0.680 |
Why?
|
Bone Diseases, Metabolic | 1 | 2019 | 33 | 0.680 |
Why?
|
Intestinal Neoplasms | 1 | 2019 | 57 | 0.670 |
Why?
|
Bariatric Surgery | 1 | 2021 | 194 | 0.660 |
Why?
|
Osteoporosis | 2 | 2019 | 122 | 0.660 |
Why?
|
Central Venous Catheters | 1 | 2019 | 23 | 0.660 |
Why?
|
Organ Transplantation | 1 | 2022 | 270 | 0.650 |
Why?
|
Organometallic Compounds | 1 | 2019 | 132 | 0.650 |
Why?
|
Nutritional Sciences | 1 | 2018 | 12 | 0.630 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 498 | 0.610 |
Why?
|
Osteogenesis | 1 | 2019 | 245 | 0.610 |
Why?
|
Gastroenterologists | 1 | 2018 | 31 | 0.600 |
Why?
|
Betacoronavirus | 1 | 2020 | 258 | 0.590 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 2019 | 692 | 0.590 |
Why?
|
Intensive Care Units | 1 | 2020 | 380 | 0.590 |
Why?
|
Diet | 1 | 2020 | 440 | 0.570 |
Why?
|
Middle Aged | 27 | 2024 | 25343 | 0.570 |
Why?
|
Fellowships and Scholarships | 1 | 2018 | 115 | 0.560 |
Why?
|
Mediastinal Diseases | 1 | 2016 | 21 | 0.550 |
Why?
|
Celiac Disease | 1 | 2019 | 207 | 0.550 |
Why?
|
Antibodies, Monoclonal | 7 | 2021 | 1393 | 0.550 |
Why?
|
Granuloma | 1 | 2016 | 65 | 0.550 |
Why?
|
Female | 39 | 2024 | 45191 | 0.530 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 316 | 0.510 |
Why?
|
Coronavirus Infections | 1 | 2020 | 301 | 0.510 |
Why?
|
Male | 36 | 2024 | 41502 | 0.510 |
Why?
|
Colonoscopy | 6 | 2024 | 272 | 0.500 |
Why?
|
Deglutition Disorders | 1 | 2016 | 117 | 0.500 |
Why?
|
Ileitis | 1 | 2014 | 7 | 0.480 |
Why?
|
Education, Medical, Graduate | 1 | 2018 | 381 | 0.470 |
Why?
|
Antibodies, Monoclonal, Humanized | 5 | 2019 | 942 | 0.460 |
Why?
|
Cystic Fibrosis | 3 | 2018 | 115 | 0.450 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2018 | 110 | 0.440 |
Why?
|
Adult | 23 | 2024 | 26018 | 0.440 |
Why?
|
Aspartate Aminotransferases | 2 | 2024 | 73 | 0.430 |
Why?
|
Aged | 18 | 2024 | 18644 | 0.430 |
Why?
|
Colorectal Neoplasms | 4 | 2023 | 955 | 0.420 |
Why?
|
Treatment Outcome | 17 | 2024 | 8054 | 0.400 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 1579 | 0.360 |
Why?
|
Calcineurin Inhibitors | 2 | 2021 | 56 | 0.350 |
Why?
|
Pharmaceutical Preparations | 2 | 2021 | 91 | 0.350 |
Why?
|
Fibrosis | 2 | 2021 | 210 | 0.350 |
Why?
|
Severity of Illness Index | 7 | 2021 | 1818 | 0.350 |
Why?
|
Abdominal Pain | 2 | 2020 | 139 | 0.330 |
Why?
|
Antirheumatic Agents | 2 | 2020 | 54 | 0.320 |
Why?
|
Weight Loss | 3 | 2019 | 224 | 0.310 |
Why?
|
Liver Cirrhosis | 3 | 2021 | 301 | 0.310 |
Why?
|
Biopsy | 3 | 2021 | 1173 | 0.310 |
Why?
|
Mesentery | 2 | 2019 | 45 | 0.300 |
Why?
|
Cholangitis, Sclerosing | 2 | 2018 | 53 | 0.290 |
Why?
|
Inpatients | 3 | 2021 | 307 | 0.290 |
Why?
|
Gastrointestinal Diseases | 2 | 2017 | 146 | 0.260 |
Why?
|
Colectomy | 2 | 2024 | 167 | 0.260 |
Why?
|
Prospective Studies | 5 | 2021 | 4232 | 0.250 |
Why?
|
Colitis, Microscopic | 1 | 2024 | 6 | 0.250 |
Why?
|
Lung Diseases, Interstitial | 2 | 2020 | 243 | 0.240 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 242 | 0.240 |
Why?
|
Budesonide | 1 | 2024 | 46 | 0.240 |
Why?
|
Alanine Transaminase | 1 | 2024 | 74 | 0.240 |
Why?
|
Risk Assessment | 5 | 2019 | 2260 | 0.240 |
Why?
|
Bilirubin | 1 | 2024 | 130 | 0.240 |
Why?
|
Adenomatous Polyps | 1 | 2023 | 12 | 0.230 |
Why?
|
Cohort Studies | 4 | 2024 | 2791 | 0.230 |
Why?
|
Adolescent, Hospitalized | 1 | 2022 | 1 | 0.220 |
Why?
|
Diarrhea | 2 | 2014 | 182 | 0.220 |
Why?
|
Gastrostomy | 1 | 2023 | 69 | 0.220 |
Why?
|
ROC Curve | 3 | 2021 | 768 | 0.210 |
Why?
|
Ulcer | 1 | 2022 | 37 | 0.210 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 55 | 0.210 |
Why?
|
Hemoglobins | 1 | 2023 | 189 | 0.210 |
Why?
|
Cytomegalovirus | 1 | 2022 | 77 | 0.210 |
Why?
|
Diverticulum | 2 | 2019 | 45 | 0.210 |
Why?
|
Adolescent | 11 | 2022 | 9080 | 0.210 |
Why?
|
Polymerase Chain Reaction | 2 | 2022 | 925 | 0.210 |
Why?
|
Young Adult | 10 | 2019 | 6117 | 0.200 |
Why?
|
Hospitals | 1 | 2024 | 295 | 0.200 |
Why?
|
Platelet Count | 1 | 2021 | 93 | 0.200 |
Why?
|
Adenoma | 1 | 2023 | 242 | 0.200 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2021 | 39 | 0.190 |
Why?
|
Double-Balloon Enteroscopy | 1 | 2021 | 11 | 0.190 |
Why?
|
Prognosis | 5 | 2022 | 3708 | 0.190 |
Why?
|
Gastrointestinal Tract | 1 | 2023 | 190 | 0.190 |
Why?
|
Propensity Score | 1 | 2021 | 140 | 0.190 |
Why?
|
Antibodies, Viral | 1 | 2022 | 302 | 0.190 |
Why?
|
Nutritional Status | 1 | 2021 | 84 | 0.190 |
Why?
|
Enteral Nutrition | 1 | 2021 | 103 | 0.190 |
Why?
|
Antiplatyhelmintic Agents | 1 | 2020 | 6 | 0.190 |
Why?
|
Biomarkers | 4 | 2021 | 1733 | 0.190 |
Why?
|
Vitamin D | 2 | 2021 | 264 | 0.180 |
Why?
|
Life Cycle Stages | 1 | 2020 | 16 | 0.180 |
Why?
|
Colonic Polyps | 1 | 2021 | 128 | 0.180 |
Why?
|
Interleukin-23 | 1 | 2020 | 56 | 0.180 |
Why?
|
Warfarin | 1 | 2020 | 103 | 0.180 |
Why?
|
Aged, 80 and over | 7 | 2023 | 6613 | 0.180 |
Why?
|
Lubricants | 1 | 2019 | 7 | 0.180 |
Why?
|
Panniculitis, Peritoneal | 1 | 2019 | 4 | 0.180 |
Why?
|
Laxatives | 1 | 2019 | 13 | 0.180 |
Why?
|
Interleukin-12 | 1 | 2020 | 109 | 0.180 |
Why?
|
Double-Blind Method | 1 | 2024 | 1707 | 0.180 |
Why?
|
Cyclosporine | 2 | 2018 | 236 | 0.180 |
Why?
|
Mesenteric Artery, Superior | 1 | 2019 | 19 | 0.180 |
Why?
|
Prevalence | 5 | 2021 | 1246 | 0.180 |
Why?
|
Vitamin D Deficiency | 1 | 2021 | 103 | 0.180 |
Why?
|
Travel | 1 | 2020 | 70 | 0.180 |
Why?
|
Mesenteric Veins | 1 | 2019 | 34 | 0.180 |
Why?
|
Respiratory Tract Infections | 1 | 2020 | 107 | 0.170 |
Why?
|
Drug Substitution | 1 | 2019 | 24 | 0.170 |
Why?
|
Radionuclide Imaging | 1 | 2019 | 221 | 0.170 |
Why?
|
Tacrolimus | 2 | 2018 | 373 | 0.170 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 165 | 0.170 |
Why?
|
Diet, Gluten-Free | 1 | 2019 | 54 | 0.170 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2020 | 126 | 0.170 |
Why?
|
Logistic Models | 3 | 2018 | 1198 | 0.170 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2019 | 68 | 0.160 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 40 | 0.160 |
Why?
|
Odds Ratio | 6 | 2017 | 682 | 0.160 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 199 | 0.160 |
Why?
|
Interleukin-17 | 1 | 2019 | 103 | 0.160 |
Why?
|
Ileum | 1 | 2019 | 159 | 0.160 |
Why?
|
Ribotyping | 2 | 2015 | 11 | 0.160 |
Why?
|
Incidence | 5 | 2021 | 1569 | 0.160 |
Why?
|
Bone Density | 1 | 2019 | 209 | 0.160 |
Why?
|
Fractures, Bone | 1 | 2019 | 122 | 0.160 |
Why?
|
Adrenal Cortex Hormones | 1 | 2019 | 264 | 0.150 |
Why?
|
Survival Rate | 1 | 2022 | 1870 | 0.150 |
Why?
|
Paraneoplastic Syndromes | 1 | 2017 | 16 | 0.150 |
Why?
|
Equipment Design | 1 | 2019 | 411 | 0.150 |
Why?
|
Pandemics | 2 | 2020 | 747 | 0.150 |
Why?
|
CTLA-4 Antigen | 1 | 2017 | 137 | 0.150 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 408 | 0.150 |
Why?
|
Carcinoma, Small Cell | 1 | 2017 | 133 | 0.140 |
Why?
|
Glucocorticoids | 2 | 2020 | 355 | 0.140 |
Why?
|
Itraconazole | 1 | 2016 | 11 | 0.140 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 1687 | 0.140 |
Why?
|
Paracentesis | 1 | 2016 | 10 | 0.140 |
Why?
|
Ambulatory Care | 1 | 2018 | 185 | 0.140 |
Why?
|
Atrial Fibrillation | 1 | 2020 | 336 | 0.140 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2017 | 164 | 0.140 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2017 | 100 | 0.140 |
Why?
|
Endoscopy | 1 | 2019 | 337 | 0.140 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 794 | 0.140 |
Why?
|
Ascites | 1 | 2016 | 57 | 0.140 |
Why?
|
Bronchoscopy | 1 | 2017 | 156 | 0.130 |
Why?
|
Registries | 1 | 2020 | 733 | 0.130 |
Why?
|
Wound Healing | 1 | 2018 | 348 | 0.130 |
Why?
|
Lymph Nodes | 1 | 2019 | 546 | 0.130 |
Why?
|
Antifungal Agents | 1 | 2016 | 118 | 0.130 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 220 | 0.130 |
Why?
|
Age Factors | 5 | 2018 | 1848 | 0.130 |
Why?
|
Women's Health | 1 | 2016 | 100 | 0.130 |
Why?
|
Botulinum Toxins | 1 | 2015 | 17 | 0.130 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 432 | 0.130 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2017 | 190 | 0.130 |
Why?
|
Pregnancy Outcome | 1 | 2016 | 252 | 0.130 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2014 | 20 | 0.120 |
Why?
|
Remission Induction | 3 | 2024 | 730 | 0.120 |
Why?
|
Intestinal Obstruction | 1 | 2015 | 87 | 0.120 |
Why?
|
Calcium | 1 | 2019 | 1170 | 0.120 |
Why?
|
History, 18th Century | 1 | 2014 | 23 | 0.120 |
Why?
|
History, 19th Century | 1 | 2014 | 60 | 0.120 |
Why?
|
Pregnancy Complications | 1 | 2016 | 343 | 0.120 |
Why?
|
Erythrocyte Transfusion | 1 | 2014 | 71 | 0.110 |
Why?
|
Calcitonin | 1 | 2013 | 38 | 0.110 |
Why?
|
Curriculum | 1 | 2018 | 551 | 0.110 |
Why?
|
Feces | 1 | 2015 | 325 | 0.110 |
Why?
|
Tertiary Care Centers | 1 | 2013 | 97 | 0.110 |
Why?
|
Frail Elderly | 1 | 2013 | 74 | 0.110 |
Why?
|
Animals | 4 | 2020 | 26951 | 0.110 |
Why?
|
Primary Health Care | 1 | 2016 | 343 | 0.110 |
Why?
|
Protein Precursors | 1 | 2013 | 143 | 0.110 |
Why?
|
History, 20th Century | 1 | 2014 | 313 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 1343 | 0.100 |
Why?
|
Immunotherapy | 1 | 2017 | 648 | 0.100 |
Why?
|
Kidney Transplantation | 1 | 2018 | 842 | 0.100 |
Why?
|
Motor Activity | 1 | 2013 | 327 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 836 | 0.100 |
Why?
|
Child | 6 | 2022 | 7039 | 0.090 |
Why?
|
Postoperative Period | 2 | 2021 | 305 | 0.090 |
Why?
|
Length of Stay | 3 | 2021 | 713 | 0.090 |
Why?
|
CD40 Antigens | 1 | 2009 | 43 | 0.090 |
Why?
|
Databases, Factual | 3 | 2019 | 837 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 2618 | 0.080 |
Why?
|
Interleukin-2 | 1 | 2009 | 250 | 0.080 |
Why?
|
Liver Function Tests | 2 | 2020 | 93 | 0.080 |
Why?
|
Recurrence | 3 | 2021 | 1162 | 0.080 |
Why?
|
Liver Transplantation | 1 | 2016 | 1285 | 0.080 |
Why?
|
Time Factors | 4 | 2018 | 5262 | 0.080 |
Why?
|
Cell Proliferation | 1 | 2014 | 1621 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 3407 | 0.080 |
Why?
|
T-Lymphocytes | 1 | 2014 | 1205 | 0.080 |
Why?
|
Antibodies | 1 | 2009 | 353 | 0.080 |
Why?
|
Interleukin-6 | 2 | 2020 | 260 | 0.070 |
Why?
|
Lung Neoplasms | 1 | 2017 | 2308 | 0.060 |
Why?
|
Colitis, Collagenous | 1 | 2024 | 2 | 0.060 |
Why?
|
Colitis, Lymphocytic | 1 | 2024 | 4 | 0.060 |
Why?
|
Proton Pump Inhibitors | 1 | 2024 | 34 | 0.060 |
Why?
|
Child, Preschool | 3 | 2018 | 3652 | 0.060 |
Why?
|
Intubation, Gastrointestinal | 1 | 2023 | 31 | 0.060 |
Why?
|
Michigan | 2 | 2013 | 53 | 0.060 |
Why?
|
Disease Progression | 2 | 2018 | 1473 | 0.050 |
Why?
|
Hospital Mortality | 2 | 2016 | 360 | 0.050 |
Why?
|
United States | 3 | 2022 | 6769 | 0.050 |
Why?
|
Pregnancy | 2 | 2020 | 2969 | 0.050 |
Why?
|
Piperidines | 1 | 2022 | 163 | 0.050 |
Why?
|
Diverticulum, Esophageal | 1 | 1981 | 5 | 0.050 |
Why?
|
Dabigatran | 1 | 2020 | 25 | 0.050 |
Why?
|
Cytoreduction Surgical Procedures | 1 | 2021 | 76 | 0.050 |
Why?
|
Morphinans | 1 | 2019 | 4 | 0.050 |
Why?
|
Cholestasis | 1 | 2020 | 46 | 0.040 |
Why?
|
Bile Acids and Salts | 1 | 2020 | 63 | 0.040 |
Why?
|
Steroids | 1 | 2020 | 175 | 0.040 |
Why?
|
Administration, Oral | 1 | 2020 | 678 | 0.040 |
Why?
|
Organ Size | 1 | 2020 | 365 | 0.040 |
Why?
|
Risk | 1 | 2020 | 660 | 0.040 |
Why?
|
Spinal Fractures | 1 | 2019 | 76 | 0.040 |
Why?
|
Dermatologic Agents | 1 | 2019 | 72 | 0.040 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2019 | 66 | 0.040 |
Why?
|
Naltrexone | 1 | 2019 | 135 | 0.040 |
Why?
|
Narcotic Antagonists | 1 | 2019 | 156 | 0.040 |
Why?
|
Life Expectancy | 1 | 2018 | 86 | 0.040 |
Why?
|
Age Distribution | 1 | 2018 | 200 | 0.040 |
Why?
|
Biological Therapy | 1 | 2018 | 46 | 0.040 |
Why?
|
Databases, Bibliographic | 1 | 2017 | 17 | 0.040 |
Why?
|
Polyethylene Glycols | 1 | 2019 | 365 | 0.040 |
Why?
|
Anticoagulants | 1 | 2020 | 421 | 0.040 |
Why?
|
Data Mining | 1 | 2017 | 42 | 0.040 |
Why?
|
Hepatitis, Chronic | 1 | 2016 | 5 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2018 | 192 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 856 | 0.040 |
Why?
|
Colon | 1 | 2020 | 499 | 0.040 |
Why?
|
Infant | 2 | 2014 | 3098 | 0.040 |
Why?
|
Induction Chemotherapy | 1 | 2017 | 148 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 900 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 984 | 0.030 |
Why?
|
Directive Counseling | 1 | 2016 | 35 | 0.030 |
Why?
|
Patient Discharge | 1 | 2019 | 310 | 0.030 |
Why?
|
Cost Savings | 1 | 2016 | 68 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 94 | 0.030 |
Why?
|
Vomiting | 1 | 2017 | 194 | 0.030 |
Why?
|
Population Surveillance | 1 | 2016 | 216 | 0.030 |
Why?
|
Hospital Costs | 1 | 2016 | 107 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 759 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2018 | 994 | 0.030 |
Why?
|
Sex Factors | 1 | 2018 | 1055 | 0.030 |
Why?
|
Patient Safety | 1 | 2017 | 212 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2020 | 799 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2020 | 1967 | 0.030 |
Why?
|
Cladribine | 1 | 2014 | 35 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 426 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 305 | 0.030 |
Why?
|
Phytohemagglutinins | 1 | 2014 | 22 | 0.030 |
Why?
|
Quality Indicators, Health Care | 1 | 2016 | 146 | 0.030 |
Why?
|
Antigens, CD1 | 1 | 2014 | 36 | 0.030 |
Why?
|
Lung Transplantation | 1 | 2018 | 249 | 0.030 |
Why?
|
Interleukin-1beta | 1 | 2014 | 78 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 339 | 0.030 |
Why?
|
CD3 Complex | 1 | 2014 | 134 | 0.030 |
Why?
|
Blood Preservation | 1 | 2014 | 10 | 0.030 |
Why?
|
CD28 Antigens | 1 | 2014 | 89 | 0.030 |
Why?
|
Gastroenteritis | 1 | 2014 | 27 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2020 | 2425 | 0.030 |
Why?
|
Drug Resistance | 1 | 2014 | 232 | 0.030 |
Why?
|
Genetic Markers | 1 | 2014 | 476 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2014 | 145 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 453 | 0.030 |
Why?
|
Gastrointestinal Microbiome | 1 | 2020 | 473 | 0.030 |
Why?
|
Chronic Disease | 1 | 2016 | 942 | 0.030 |
Why?
|
Chicago | 1 | 2018 | 1394 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2014 | 155 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2013 | 225 | 0.030 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2014 | 181 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2014 | 167 | 0.030 |
Why?
|
Calcitonin Gene-Related Peptide | 1 | 2013 | 39 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 531 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2014 | 389 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2014 | 292 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 3161 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 332 | 0.030 |
Why?
|
Mice | 2 | 2020 | 11586 | 0.020 |
Why?
|
Models, Statistical | 1 | 2015 | 574 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 1956 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2021 | 2236 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2014 | 424 | 0.020 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 2009 | 9 | 0.020 |
Why?
|
Chemokine CXCL9 | 1 | 2009 | 7 | 0.020 |
Why?
|
Chemokine CCL5 | 1 | 2009 | 16 | 0.020 |
Why?
|
Receptors, Cytokine | 1 | 2009 | 28 | 0.020 |
Why?
|
Arginase | 1 | 2009 | 16 | 0.020 |
Why?
|
Receptors, CCR2 | 1 | 2009 | 35 | 0.020 |
Why?
|
Chemokines, CC | 1 | 2009 | 36 | 0.020 |
Why?
|
Chemokines | 1 | 2009 | 74 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2014 | 1834 | 0.020 |
Why?
|
Drug Synergism | 1 | 2009 | 303 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2014 | 2842 | 0.020 |
Why?
|
Signal Transduction | 1 | 2020 | 3327 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2009 | 126 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2009 | 1073 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2012 | 1674 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2009 | 436 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2013 | 3640 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2012 | 2734 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2009 | 582 | 0.020 |
Why?
|
Mutation | 1 | 2014 | 4061 | 0.010 |
Why?
|